Takeda Pharmaceutical Company Limited American Depositary Shares (each

TAK Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of TAK by members of U.S. Congress

Politician Type Traded
Virginia Foxx House / R Sale $15,001 - $50,000 Aug 29, 2023
Daniel S. Goldman House / D Sale $15,001 - $50,000 Jul 10, 2023
Virginia Foxx House / R Purchase $1,001 - $15,000 Feb 16, 2023
Virginia Foxx House / R Purchase $1,001 - $15,000 Nov 01, 2022
Greg Gianforte House / R Sale $1,001 - $15,000 Sep 11, 2019
Nicholas V. Taylor House / R Sale $15,001 - $50,000 Mar 25, 2019
Greg Gianforte House / R Purchase $15,001 - $50,000 Dec 21, 2018
TAK Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
TAK Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
TAK Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in TAK holdings by institutional investors

Insider Trading

Quarterly net insider trading by TAK's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $590,000 Jan 20, 2026 Issue: Budget/Appropriations Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
  • $1,370,000 Oct 20, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
  • $1,570,000 Aug 26, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
  • $490,000 Apr 22, 2025 Issue: Budget/Appropriations Taxation/Internal Revenue Code Trade (domestic/foreign) Defense Medicare/Medicaid Health Issues
  • $390,000 Apr 18, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
  • $970,000 Oct 18, 2024 Issue: Budget/Appropriations Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $1,050,000 Jul 22, 2024 Issue: Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $510,000 Jan 19, 2024 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $1,380,000 Oct 20, 2023 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
Corporate Lobbying

TAK Estimated quarterly lobbying spending

Revenue Breakdown

TAK Revenue by Segment or Geography

By Segment
By Geography
TAK Income Statement
TAK Balance Sheet
TAK Cash Flow
U.S. Patents

New TAK patent grants

  • Patent Title: Substituted pyrido[2,3-b]pyrazines Sep. 02, 2014
  • Patent Title: Tablet containing hardly soluble active ingredient Sep. 02, 2014
  • Patent Title: Controlled release composition and method of producing the same Aug. 26, 2014
  • Patent Title: Salts of benzimidazole compound and use thereof Aug. 19, 2014
  • Patent Title: Apoptosis signal-regulating kinase 1 inhibitors Aug. 12, 2014
  • Patent Title: N-substituted oxazinopteridines and oxazinopteridinones Jul. 29, 2014
  • Patent Title: Tricyclic compounds and use thereof Jul. 22, 2014
  • Patent Title: Controlled release preparation Jul. 22, 2014
  • Patent Title: Pyridazinone compounds Jul. 15, 2014
  • Patent Title: Heterocyclic compound and use thereof Jul. 15, 2014
  • Patent Title: Metastin derivatives and use thereof Jul. 15, 2014
  • Patent Title: Nitrogen-containing heterocyclic compound Jul. 08, 2014
  • Patent Title: Metastin derivatives and use thereof Jul. 01, 2014
  • Patent Title: Thienopyrimidine compounds and use thereof May. 27, 2014
  • Patent Title: Bicyclic compound May. 20, 2014
  • Patent Title: Heterocyclic compounds May. 13, 2014
  • Patent Title: Heterocyclic compound May. 13, 2014
  • Patent Title: Controlled release preparation May. 13, 2014
  • Patent Title: Bicyclic compound Apr. 22, 2014
  • Patent Title: Heterocyclic compound and use thereof Apr. 15, 2014
  • Patent Title: Cyclic amide derivative, and its production and use Apr. 15, 2014
  • Patent Title: Tablet preparation without causing a tableting trouble Apr. 15, 2014
  • Patent Title: Stable solid preparations Apr. 15, 2014
  • Patent Title: Stable solid preparations Apr. 15, 2014
  • Patent Title: Thienopyrimidine as cdc7 kinase inhibitors Apr. 08, 2014
  • Patent Title: Diphosphine ligand and transition metal complex using the same Apr. 08, 2014
  • Patent Title: Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors Apr. 01, 2014
  • Patent Title: Preventives/remedies for stress urinary incontinence and method of screening the same Apr. 01, 2014
  • Patent Title: Fused ring compounds and use thereof Mar. 18, 2014
  • Patent Title: Poly (adp-ribose) polymerase (parp) inhibitors Mar. 11, 2014
  • Patent Title: Heterocyclic compound and use thereof Mar. 04, 2014
  • Patent Title: Process for producing nucleoside Feb. 18, 2014
  • Patent Title: Heterocyclic compounds Feb. 11, 2014
  • Patent Title: Indole derivative Feb. 04, 2014
  • Patent Title: Orally dispersible tablet Feb. 04, 2014
  • Patent Title: Orally dispersible tablet Feb. 04, 2014
  • Patent Title: Method for treating a disease characterized by reduced appetite Feb. 04, 2014
  • Patent Title: Solid preparation comprising alogliptin and pioglitazone Jan. 28, 2014
  • Patent Title: Sustained-release preparation Jan. 28, 2014
  • Patent Title: Taste-masking solid preparation of pioglitazone Jan. 21, 2014
  • Patent Title: Finely divided composition containing poorly water soluble substance Jan. 07, 2014
  • Patent Title: Hsp90 inhibitors Dec. 31, 2013
  • Patent Title: Fused heterocyclic ring derivative and use thereof Dec. 24, 2013
  • Patent Title: Process for production of optically active amine derivatives Dec. 17, 2013
  • Patent Title: Fused cyclic compounds Dec. 03, 2013
  • Patent Title: Method of producing a crystal of an imidazole compound Nov. 26, 2013
  • Patent Title: Pyrrole compounds Nov. 26, 2013
  • Patent Title: Nitrogen-containing heterocyclic compound and use of same Nov. 26, 2013
  • Patent Title: Cyclic amine compound Nov. 26, 2013
  • Patent Title: Fused ring compound and use thereof Nov. 26, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to TAK from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
TAK News

Recent insights relating to TAK

CNBC Recommendations

Recent picks made for TAK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TAK

TAK Analyst Ratings

TAK Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
TAK Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $TAK stock a Buy, Sell, or Hold?

  • What is the price target for $TAK stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

TAK Top Shareholders
Shareholder
Shares Held
TAK Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $TAK stock?

  • Who owns the most shares of $TAK stock?

  • What funds own $TAK stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

TAK Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view TAK Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About TAK

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Company Limited American Depositary Shares (each Executive Compensation
Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation